Share

September 14, 2021; 97 (11) Editorial

Clinical Efficacy, Drug Safety, and Surrogate Endpoints

Has Aducanumab Met All of Its Expectations?

Linda A. Hershey, Rawan Tarawneh
First published July 7, 2021, DOI: https://doi.org/10.1212/WNL.0000000000012453
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1449

Share

Article Information

vol. 97 no. 11 517-518
DOI: 
https://doi.org/10.1212/WNL.0000000000012453
PubMed: 
34233940
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published July 7, 2021.

Article Versions

Copyright & Usage: 
© 2021 American Academy of Neurology

Author Disclosures

    1. Linda A. Hershey, MD, PhD and
    2. Rawan Tarawneh, MD
  1. Linda A. Hershey, MD, PhD and
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. I have served as an Associate Editor for Neurology since 2019. Editorial board of Neurology from 2011-2019. Editorial boards of JSM Alzheimer's Disease & Related Dementia (2014-present) and J Neuroscience & Cognitive Studies (2017-present). I served as a peer-reviewer in 2019 for MKSAP-18 (American College of Physicians). In 2018, I received compensation for a special review for the Annals of Internal Medicine (American College of Physicians).

    Patents:

    1. NONE

    Publishing Royalties:

    1. Royalties for writing annual updates for MedLink Neurology about these 4 topics: a) Memory Loss (2015-present) b) Cognitive and behavioral changes in PSP (2015-present) c) Sleep and dementia (2017-present) d) Pre-MCI (2019-present) e) Vascular cognitive impairment (2020-present)

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. a) I have served on the Network of Experts (about the design of Alzheimer studies) for the FDA since 2018. b) I served as a member of the Long Term Care Stakeholders Committee for the Oklahoma Foundation for Medical Quality from 2017-20.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical procedures or imaging studies:

    1. I held an endowed chair at OU from 2010-2015: Ethelyn McElwee Endowed Chair in Alzheimer's Disease Research, University of Oklahoma Health Sciences Center and was the Director of Dementia & Behavioral Neurology at OU Physicians.

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Rawan Tarawneh, MD
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. 1. Editorial Board Member for Biomarker Insights (SAGE) Journal, 4/2021-current 2. Editorial Board Member Open Biomarkers Journal (Bentham) 2019-2020 3. Healio Peer Perspective Board for Neurology, 2021-current

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. PI on NIH grant: R21AG067755-01A1 (Multiple PI: Tarawneh/Amer)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (L.A.H.), University of Oklahoma Health Sciences Center, Oklahoma City; and Department of Neurology (R.T.), The Ohio State University, Columbus.
  1. Correspondence
    Dr. Hershey linda-hershey{at}ouhsc.edu
View Full Text

Article usage

Article usage: July 2021 to March 2023

AbstractFullPdfSource
Jul 202100373Highwire
Aug 202100141Highwire
Sep 20215991249Highwire
Oct 202111962124Highwire
Nov 20211320199Highwire
Dec 20211212960Highwire
Jan 20221811661Highwire
Feb 20221316733Highwire
Mar 202299149Highwire
Apr 202285942Highwire
May 2022106526Highwire
Jun 202224314Highwire
Jul 202244725Highwire
Aug 2022104848Highwire
Sep 2022115527Highwire
Oct 2022115621Highwire
Nov 2022155720Highwire
Dec 202273611Highwire
Jan 202372911Highwire
Feb 202332915Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Alert Me

Recommended articles